Research ExplorerPublicationsLate presentation for HIV diagnosis and care in Germany.

Late presentation for HIV diagnosis and care in Germany.

Standard

Late presentation for HIV diagnosis and care in Germany. / Zoufaly, Alexander; An der Heiden, M; Marcus, U; Hoffmann, C; Stellbrink, Hj; Voss, L; van Lunzen, Jan; Hamouda, O; Group, ClinSurv Study.

In: HIV MED, Vol. 13, No. 3, 3, 2012, p. 172-181.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Zoufaly, A, An der Heiden, M, Marcus, U, Hoffmann, C, Stellbrink, H, Voss, L, van Lunzen, J, Hamouda, O & Group, CS 2012, 'Late presentation for HIV diagnosis and care in Germany.', HIV MED, vol. 13, no. 3, 3, pp. 172-181. <http://www.ncbi.nlm.nih.gov/pubmed/22093171?dopt=Citation>

APA

Zoufaly, A., An der Heiden, M., Marcus, U., Hoffmann, C., Stellbrink, H., Voss, L., van Lunzen, J., Hamouda, O., & Group, C. S. (2012). Late presentation for HIV diagnosis and care in Germany. HIV MED, 13(3), 172-181. [3]. http://www.ncbi.nlm.nih.gov/pubmed/22093171?dopt=Citation

Vancouver

Zoufaly A, An der Heiden M, Marcus U, Hoffmann C, Stellbrink H, Voss L et al. Late presentation for HIV diagnosis and care in Germany. HIV MED. 2012;13(3):172-181. 3.

Bibtex

@article{adcb9276e2804c979721396f9324273c,
title = "Late presentation for HIV diagnosis and care in Germany.",
abstract = "Antiretroviral therapy reduces mortality and morbidity in HIV-infected individuals most markedly when initiated early, before advanced immunodeficiency has developed. Late presentation for diagnosis and care remains a significant challenge. To guide public health interventions effectively it is crucial to describe the factors associated with late presentation.",
keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Risk Factors, Cohort Studies, Population Surveillance, CD4 Lymphocyte Count, Public Health, Germany/epidemiology, Anti-HIV Agents/*therapeutic use, Delayed Diagnosis/*statistics & numerical data, HIV Protease Inhibitors/therapeutic use, HIV Seropositivity/*diagnosis/*drug therapy/epidemiology, Reverse Transcriptase Inhibitors/*therapeutic use, Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Risk Factors, Cohort Studies, Population Surveillance, CD4 Lymphocyte Count, Public Health, Germany/epidemiology, Anti-HIV Agents/*therapeutic use, Delayed Diagnosis/*statistics & numerical data, HIV Protease Inhibitors/therapeutic use, HIV Seropositivity/*diagnosis/*drug therapy/epidemiology, Reverse Transcriptase Inhibitors/*therapeutic use",
author = "Alexander Zoufaly and {An der Heiden}, M and U Marcus and C Hoffmann and Hj Stellbrink and L Voss and {van Lunzen}, Jan and O Hamouda and Group, {ClinSurv Study}",
year = "2012",
language = "English",
volume = "13",
pages = "172--181",
journal = "HIV MED",
issn = "1464-2662",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Late presentation for HIV diagnosis and care in Germany.

AU - Zoufaly, Alexander

AU - An der Heiden, M

AU - Marcus, U

AU - Hoffmann, C

AU - Stellbrink, Hj

AU - Voss, L

AU - van Lunzen, Jan

AU - Hamouda, O

AU - Group, ClinSurv Study

PY - 2012

Y1 - 2012

N2 - Antiretroviral therapy reduces mortality and morbidity in HIV-infected individuals most markedly when initiated early, before advanced immunodeficiency has developed. Late presentation for diagnosis and care remains a significant challenge. To guide public health interventions effectively it is crucial to describe the factors associated with late presentation.

AB - Antiretroviral therapy reduces mortality and morbidity in HIV-infected individuals most markedly when initiated early, before advanced immunodeficiency has developed. Late presentation for diagnosis and care remains a significant challenge. To guide public health interventions effectively it is crucial to describe the factors associated with late presentation.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Risk Factors

KW - Cohort Studies

KW - Population Surveillance

KW - CD4 Lymphocyte Count

KW - Public Health

KW - Germany/epidemiology

KW - Anti-HIV Agents/therapeutic use

KW - Delayed Diagnosis/statistics & numerical data

KW - HIV Protease Inhibitors/therapeutic use

KW - HIV Seropositivity/diagnosis/drug therapy/epidemiology

KW - Reverse Transcriptase Inhibitors/therapeutic use

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Risk Factors

KW - Cohort Studies

KW - Population Surveillance

KW - CD4 Lymphocyte Count

KW - Public Health

KW - Germany/epidemiology

KW - Anti-HIV Agents/therapeutic use

KW - Delayed Diagnosis/statistics & numerical data

KW - HIV Protease Inhibitors/therapeutic use

KW - HIV Seropositivity/diagnosis/drug therapy/epidemiology

KW - Reverse Transcriptase Inhibitors/therapeutic use

M3 - SCORING: Journal article

VL - 13

SP - 172

EP - 181

JO - HIV MED

JF - HIV MED

SN - 1464-2662

IS - 3

M1 - 3

ER -